A CRISPR Therapy Just Cured A Disease From Inside The Body For The First Time. The Gene-Editing Era Officially Started Monday ...
Crispr Therapeutics (CRSP) is downgraded to "Hold" as current valuation already reflects optimism for CTX310 Phase I results and pipeline progress. Intellia Therapeutics (NTLA) maintains a "Buy" ...
Crispr Therapeutics AG is positioned for a revenue inflection as Casgevy ramps in 2026, following earlier FDA/EMA approvals for SCD and TDT. Analysts are underestimating the Casgevy revenue ramp. CRSP ...
With the arrival of CRISPR, they can alter the genes of a wide range of organisms with relative precision and ease. In the past two years alone, the prospect of gene-edited monkeys, mammoths, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results